Effects of treatment outcome in acute phase of depression on residual symptoms in a 6-month follow-up: a national, multicenter study
10.3760/cma.j.cn113661-20200306-00092
- VernacularTitle:抑郁症急性期治疗结局对残留症状变化的影响：一项来自全国、多中心的随访调查研究
- Author:
Le XIAO
1
;
Xuequan ZHU
;
Lei FENG
;
Yuan FENG
;
Wenyuan WU
;
Gang WANG
Author Information
1. 首都医科大学附属北京安定医院 国家精神心理疾病临床医学研究中心 100088
- Publication Type:Journal Article
- Keywords:
Depressive disorder;
Anxiety;
Sexual dysfunction, physiological;
Cognition;
Residual symptoms
- From:
Chinese Journal of Psychiatry
2021;54(1):9-16
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect of the acute treatment outcome on the trajectory of residual symptoms for major depressive disorder (MDD).Method:This is a multicenter, prospective, non-intervention study. The MDD patients who self-reported an improvement after received an 8-12 weeks antidepressant treatment were included. Social-demographic and clinical characteristics were collected at the baseline. Brief 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR 16), Generalized Anxiety Disorder Scale (GAD-7), Arizona Sexual Experience Scale experience (ASEX), Digital Span Test (DST) and Digit Symbol Substitution Test (DSST) were used to assess the symptoms. Patients were followed up at month 1, 3 and 6. Mix effect model and generalized estimating equation were used to analysis changes over visits of symptoms within or between groups. Result:Totally, 428 eligible patients were included in this study. At baseline, 179 patients achieved remission (41.8%,179/428) and 249 achieved partial remission (58.2%,249/428). There were no significant differences in demographics, clinical characteristics and treatment between the two groups. The proportion of increased appetite, weight gain, suicidal ideation, and restlessness in the remission group did not change significantly over time ( Z=-1.62-1.34, all P>0.003), meanwhile, the proportion of hypersomnia, increased appetite, and weight gain in the partial remission group did not change significantly over the course of the assessments ( Z=-2.43- -1.26, all P>0.003). The proportion of other residual symptoms changed significantly from baseline to 6-month follow-up in both groups ( Z=-10.77- -2.46, all P<0.003), nevertheless, there was no significant difference between the two groups ( Z=0.37-3.26, all P>0.003). The total score of GAD-7 of the two groups were significantly different at each assessment timepoint (χ 2=24.68-113.80, P<0.01), and the improvement of anxiety in the remission group was better than that in the partial remission group ( F=8.39, P<0.01). There were no significant differences in the total ASEX scores between the two groups at each visit ( F=-1.93- -0.68, all P>0.05), and there were no significant difference within the group ( F=0.01-0.17, P>0.05). There was no significant difference in the total scores of DST and DSST between the two groups at baseline ( F=-1.23, -1.14, all P>0.05), and also no significant differences were found during all follow-up visits after control for score at baseline ( F=-1.14- -0.91, all P>0.05). Conclusions:The treatment outcome of the acute phase has an impact on the residual symptoms of MDD. Remission has a positive effect on the improvement of anxiety, but has no significant effect on the improvement of sexual dysfunction and cognitive function.
